Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2026
Tyenne arthritis injection vials recalled nationwide over glass particles
Recall announced
The FDA warned that 400 mg/20 mL Tyenne (tocilizumab-aazg) injection vials, lot 16UI07, are being recalled nationwide after an internal investigation at the manufacturer found glass particles in the affected vials. The FDA said administering a recalled vial can cause local irritation, pain or swelling at the infusion site, vein inflammation, and in serious cases blocked blood flow, pulmonary embolism, permanent organ damage or death. No injuries or illnesses had been reported at the time.
Company response
Recall — Tyenne
Injection vials of the prescription arthritis medication Tyenne are being recalled nationwide, according to the U.S. Food & Drug Administration (FDA).
Source excerpt
the drug is being recalled after an internal investigation at the manufacturer found glass particles in the affected vials
The recall includes 400 mg/20 mL Tyenne injection vials, which were distributed nationwide to wholesalers, distributors, and direct customers.
Injection vials of the prescription arthritis medication Tyenne are being recalled nationwide, according to the U.S. Food & Drug Administration (FDA).